1036 related articles for article (PubMed ID: 22309967)
41. Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults.
Park YA; Waldrum MR; Marques MB
Am J Clin Pathol; 2010 Mar; 133(3):460-5. PubMed ID: 20154285
[TBL] [Abstract][Full Text] [Related]
42. Haemolytic uremic syndrome: diagnosis and management.
Sheerin NS; Glover E
F1000Res; 2019; 8():. PubMed ID: 31598213
[TBL] [Abstract][Full Text] [Related]
43. [Clinical analysis on thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, with plasma level of cytokine].
Wada H; Saitoh M; Tamaki S; Masuya M; Morita K; Tabata M; Tanigawa M; Kageyama S; Tsuzi K; Ohta C
Rinsho Ketsueki; 1990 Sep; 31(9):1537-43. PubMed ID: 2246829
[TBL] [Abstract][Full Text] [Related]
44. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
[TBL] [Abstract][Full Text] [Related]
45. [Hemolytic uremic syndrome in adults].
Hertig A; Ridel C; Rondeau E
Nephrol Ther; 2010 Jul; 6(4):258-71. PubMed ID: 20399168
[TBL] [Abstract][Full Text] [Related]
46. Plasma manipulation in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.
Remuzzi G; Ruggenenti P
Ann Med Interne (Paris); 1992; 143 Suppl 1():19-26. PubMed ID: 1300882
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic plasmapheresis for the treatment of the thrombotic thrombocytopenic purpura-haemolytic uraemic syndromes.
Hwang WY; Chai LY; Ng HJ; Goh YT; Tan PH
Singapore Med J; 2004 May; 45(5):219-23. PubMed ID: 15143357
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura: a retrospective multicenter study.
Korkmaz S; Keklik M; Sivgin S; Yildirim R; Tombak A; Kaya ME; Acik DY; Esen R; Hacioglu SK; Sencan M; Kiki I; Tiftik EN; Kuku I; Okan V; Yilmaz M; Demir C; Sari I; Altuntas F; Unal A; Ilhan O
Transfus Apher Sci; 2013 Jun; 48(3):353-8. PubMed ID: 23602056
[TBL] [Abstract][Full Text] [Related]
49. Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies.
Moake J
Best Pract Res Clin Haematol; 2009 Dec; 22(4):567-76. PubMed ID: 19959109
[TBL] [Abstract][Full Text] [Related]
50. Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Franchini M; Zaffanello M; Veneri D
Thromb Res; 2006; 118(2):177-84. PubMed ID: 16126255
[TBL] [Abstract][Full Text] [Related]
51. [Diagnosis and management of thrombotic microangiopathies].
Matsumoto M
Rinsho Ketsueki; 2015 Oct; 56(10):2092-9. PubMed ID: 26458449
[TBL] [Abstract][Full Text] [Related]
52. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis.
Laurence J
Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 17):1-12. PubMed ID: 23187605
[TBL] [Abstract][Full Text] [Related]
53. [Therapy for children with Shiga toxin-E. coli-associated hemolytic uremic syndrome].
Ito K; Hattori M; Matsumoto N
Nihon Rinsho; 2002 Jun; 60(6):1126-30. PubMed ID: 12078084
[TBL] [Abstract][Full Text] [Related]
54. The renal manifestations and outcome of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in adults.
Conlon PJ; Howell DN; Macik G; Kovalik EC; Smith SR
Nephrol Dial Transplant; 1995; 10(7):1189-93. PubMed ID: 7478122
[TBL] [Abstract][Full Text] [Related]
55. [The revolution of monoclonal antibodies in the treatment of thrombotic microangiopathy].
Sauvètre G; Grange S; Froissart A; Veyradier A; Coppo P; Benhamou Y
Rev Med Interne; 2015 May; 36(5):328-38. PubMed ID: 25547956
[TBL] [Abstract][Full Text] [Related]
56. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies.
Cataland SR; Wu HM
Eur J Intern Med; 2013 Sep; 24(6):486-91. PubMed ID: 23739653
[TBL] [Abstract][Full Text] [Related]
57. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
Intern Med J; 2018 Jun; 48(6):624-636. PubMed ID: 29582550
[TBL] [Abstract][Full Text] [Related]
58. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.
Scully M; Cataland S; Coppo P; de la Rubia J; Friedman KD; Kremer Hovinga J; Lämmle B; Matsumoto M; Pavenski K; Sadler E; Sarode R; Wu H;
J Thromb Haemost; 2017 Feb; 15(2):312-322. PubMed ID: 27868334
[TBL] [Abstract][Full Text] [Related]
59. De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival.
Caires RA; Marques ID; Repizo LP; Sato VA; Carmo LP; Machado DJ; de Paula FJ; Nahas WC; David-Neto E
Transplant Proc; 2012 Oct; 44(8):2388-90. PubMed ID: 23026601
[TBL] [Abstract][Full Text] [Related]
60. Thrombotic microangiopathy in a 17-year-old patient: TTP, HUS or a bit of both?
Gerth J; Busch M; Oyen F; Schneppenheim R; Keller T; Budde U; Groene HJ; Wolf G
Clin Nephrol; 2007 Dec; 68(6):405-11. PubMed ID: 18184524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
